Regen BioPharma Inc financial data

Symbol
RGBP, RGBPP on OTC
Location
4700 Spring St #304, La Mesa, CA
State of incorporation
NV
Fiscal year end
September 30
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.6 % -17.4%
Debt-to-equity -104 % +3.07%
Return On Equity 17.5 %
Return On Assets -450 % -234%
Operating Margin -309 % +34.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 4.51M shares +33.3%
Common Stock, Shares, Outstanding 4.37M shares +29.3%
Entity Public Float 6.59M USD
Common Stock, Value, Issued 439 USD +29.5%
Weighted Average Number of Shares Outstanding, Basic 4.21M shares +24.6%
Weighted Average Number of Shares Outstanding, Diluted 4.21M shares +24.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 127K USD -17.8%
Revenue from Contract with Customer, Excluding Assessed Tax 31.6K USD 0%
Research and Development Expense 155K USD -35.5%
General and Administrative Expense 46.6K USD +1.7%
Costs and Expenses 627K USD -34.8%
Operating Income (Loss) -391K USD +46.1%
Nonoperating Income (Expense) -227K USD -111%
Net Income (Loss) Attributable to Parent -927K USD -166%
Earnings Per Share, Basic -0.03 USD/shares 0%
Earnings Per Share, Diluted -0.03 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 51.2K USD -93%
Accounts Receivable, after Allowance for Credit Loss, Current 67.1K USD +18.7%
Assets, Current 152K USD +143%
Assets 170K USD -40.3%
Accounts Payable, Current 29.4K USD +0.04%
Liabilities, Current 5.33M USD +0.26%
Liabilities 5.33M USD +0.26%
Retained Earnings (Accumulated Deficit) -20.4M USD -4.77%
Stockholders' Equity Attributable to Parent -5.16M USD -2.56%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest -5.18M USD -4.99%
Liabilities and Equity 170K USD -40.3%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -162K USD -1452%
Net Cash Provided by (Used in) Financing Activities 166K USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 500M shares -91.4%
Common Stock, Shares, Issued 4.37M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 61.8K USD +8838%
Deferred Tax Assets, Valuation Allowance 4.15M USD -5.53%
Deferred Tax Assets, Gross 4.15M USD -5.53%
Deferred Tax Assets, Operating Loss Carryforwards 4.15M USD -5.53%
Preferred Stock, Shares Authorized 800M shares 0%
Additional Paid in Capital 14.5M USD +5.85%
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Interest Expense 64K USD -29.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%